Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nuro Pharma
AddedFeb 18, 2024
UpdatedJun 18, 2026
Nuro Pharma

Nuro Pharma

Seed

NuroPharma: A dedicated home pharmacy ensuring consistent, quality epilepsy medication, prioritizing patient safety over profit.

HQ
Las Vegas, NV, US
Founded
2012
Overview
Compare
Fundraising
Employees

Nuro Pharma is dedicated to providing concierge pharmacy care, specifically tailored for neurologists and their epilepsy patients. The company offers both branded and generic pharmaceutical products through an exclusive home pharmacy service. Specializing in generic seizure medications, Nuro Pharma ensures consistent quality, prioritizing patient safety over profit, unlike retail and mail-order pharmacies that may switch manufacturers to maximize revenue.

Nuro Pharma has made significant strides in the epilepsy care market by ensuring that patients receive consistent medication, which is crucial for managing their condition effectively. This focus on quality and patient safety has garnered trust and recognition within the medical community, particularly among neurologists and their patients.

Nuro Pharma - Quick Facts

When was Nuro Pharma founded?

Nuro Pharma was founded in 2012.

Where is Nuro Pharma's headquarters located?

Nuro Pharma's headquarters is located in Las Vegas, NV, US.

When was Nuro Pharma's last funding round?

Nuro Pharma's most recent funding round was for $80k (USD) in June 2013.

How much has Nuro Pharma raised to-date?

As of Jun 19, 2013, Nuro Pharma has raised a total of $738.4k (USD).

How many employees does Nuro Pharma have?

Nuro Pharma has 30 employees as of Feb 5, 2024.

Nuro Pharma - Classification

Ownership
  • Private
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Consumers
Main Product
  • Medication
  • Pharmacy
Tags
  • eCommerce
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 22 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 456000Health and Personal Care Retailers
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 450000Retail Trade
  • 325000Chemical Manufacturing
  • 541000Professional, Scientific, and Technical Services
  • 456100Health and Personal Care Retailers
  • 541700Scientific Research and Development Services
  • 325410Pharmaceutical and Medicine Manufacturing
  • 456110Pharmacies and Drug Retailers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 5900Miscellaneous Retail
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 2830Drugs
  • 5910Drug Stores And Proprietary Stores
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8731Commercial Physical and Biological Research